LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ...

Agricultural Microbials Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Agricultural Microbials Market is poised for strong growth due to rising demand for sustainable food systems and ...

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
The Aviationist

U.S. Approves Potential $2.3 Billion P-8A Poseidon Sale to Singapore

The U.S. has approved a possible $2.3B Foreign Military Sale to Singapore for up to four P-8A Poseidon aircraft and MK 54 ...

Aytu BioPharma, Inc.: Aytu BioPharma Recaps Investor Day Held on January 20, 2026

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n ...